InvestorsHub Logo
Followers 9
Posts 336
Boards Moderated 0
Alias Born 07/18/2016

Re: None

Monday, 09/04/2017 10:26:09 AM

Monday, September 04, 2017 10:26:09 AM

Post# of 461362
I'm not sure if this information has already been reported but it's new to me via a Facebook group post, as follows...

An invention submitted from Dr. Missling himself approuved in the European patent register on August 3 and with some diseases which were unmentioned until now: "This invention addresses tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73, AV2-73, or A2-73), ANAVEX1-41 and/or Anavex19-144 in a method of treatment for neurodevelopmental disorders. Particular reference is made to the treatment of autism spectrum disorder, cerebral palsy, Rett syndrome, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Smith-Magenis syndrome. Additional reference is made to multiple sclerosis": https://worldwide.espacenet.com/publicationDetails/biblio?II=2&ND=3&adjacent=true&locale=en_EP&FT=D&date=20170803&CC=WO&NR=2017132127A1&KC=A1#
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News